Vantage logo

Prame looks like the real deal

But can the novel antigen be targeted effectively? Immatics reckons it can, with the right dose and the right manufacturing process.

Vantage logo

Cytokine players keep the faith

The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.